Review decisions

Showing 220 results of 292 total
Summary Safety Review - KOGENATE FS/HELIXATE FS (Antihemophilic Factor [Recombinant]) - Assessing the Potential Changes in the Known Risk of Inhibitors (Inhibitory Antibody - IA) Development in Previously Untreated Patients with Severe Hemophilia A
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00116
Issued / Original Publication Date: 2016-07-26
Summary Safety Review - DICLECTIN (doxylamine and pyridoxine combination) - Assessing Safety in pregnancy
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00117
Issued / Original Publication Date: 2016-07-15
Updated Date: 2016-07-19
Summary Safety Review - Alpha Lipoic Acid - Assessing the Potential Risk of Low Blood Sugar (Hypoglycemic Episodes)
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00089
Issued / Original Publication Date: 2016-06-30
Summary Safety Review - AVONEX (interferon beta-1a) - Assessing the Potential Risk of Kidney Damage (nephrotic syndrome)
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00090
Issued / Original Publication Date: 2016-06-30
Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00091
Issued / Original Publication Date: 2016-06-13
Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00092
Issued / Original Publication Date: 2016-06-06
Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00093
Issued / Original Publication Date: 2016-06-06
Summary Safety Review - TYSABRI (natalizumab) - Assessing the Potential Risk of Hemolytic Anemia
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00094
Issued / Original Publication Date: 2016-06-06
Summary Safety Review - ESSURE Permanent Birth Control System - Assessing the Risk of Complications Including Allergic Reactions, Abnormal Bleeding/Menstrual Changes and the Potential Need for Device Removal
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00061
Issued / Original Publication Date: 2016-05-25
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00013
Issued / Original Publication Date: 2016-05-16

Displaying 211 - 220 of 292 | Page 22 of 30
Report a problem or mistake on this page
Please select all that apply:
Date modified: